ASPI is trading at approximately $6.00 (down 6%), extending a sharp decline following its strategic merger and $50 million private placement announcement.
- The stock is under pressure as investors digest potential dilution and integration risks associated with combining Noble Africa LLC and Renergen Limited with ENDRA Life Sciences.
- The downward move follows heavy trading volume and persistent weakness amid a cautious broader market sentiment.